- |||||||||| ALZ-101 / Alzinova
Biomarker, Clinical, Journal: Developing Topics. (Pubmed Central) - Jan 12, 2025 P1 oligomer-specific humoral immune response that has an impact on several biomarkers associated with disease progression. Taken together, these findings support further development of ALZ-101 as a potential novel disease-modifying treatment for patients with AD.
- |||||||||| ALZ-101 / Alzinova
PRE-CLINICAL AND INTERIM CLINICAL PHASE 1 ANTIBODY TITRE ANALYSIS OF ANTI-AMYLOID BETA OLIGOMER VACCINE ALZ-101 (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1452; P1 Four late -stage clinical trials on monoclonal antibodies have recently provided similar aducanumab, lecanemab, gantenerumab, and donanemab; all reducing plaque load, but with questionable safety and very modest clinical efficacy... The current evidence supports the continued clinical development of ALZ -101 as a specific, long -acting, and safe immunotherapy for targeting toxic Abeta oligomers in AD.
- |||||||||| ALZ-201, A MONOCLONAL ANTIBODY THERAPY FOR SPECIFIC NEUTRALISATION OF TOXIC AMYLOID-Β IN ALZHEIMER’S DISEASE. () - Oct 5, 2022 - Abstract #CTAD2022CTAD_201;
P1 We previously demonstrated that ALZ-201 specifically binds to a toxic species in post-mortem AD brain extracts to cause a positive physiological and protective impact on the integrity and morphology of mouse neurons. Biosimilars of aducanumab, lecanemab, and gantenerumab, on the other hand, were here shown to exhibit no conformational preference for Aβ, indicating that their weak binding to non-aggregated forms stem almost exclusively from fast binding off-rates.
|